Warning: Undefined variable $page_cluster_id in /home3/thegood9/public_html/website_70aad9ea/header.php on line 29



Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Tag Directory / RESEARCHFUNDING     showing 1–6 of 6   RSS


for: Saturday, March 21, 2026



Vivek Subbiah: New Nature Study on Thymic Health and Response

oncodaily - Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn: “Wow published in NATURE journal ‘Thymic health and immunotherapy outcomes in patients […]

AI Summary: A new Nature study reveals that adult thymic health materially affects immune aging and responses to cancer treatment. Researchers show thymic integrity correlates with stronger immune surveillance and better therapy outcomes, reviving interest in thymus-targeted interventions. Experts describe the finding as a necessary reappraisal of an organ long written off by adult medicine — cue the applause.


Aging immunity: why older immune systems fail us

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress


Front lines: new targets and tactics in cancer immunotherapy

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress

2 months / oncodaily

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress


On the ground: adult thymus drives longevity and therapy success

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / medicalxpress


All Other Stories

2 months / oncodaily



TerraPower Isotopes Invests $450M in Actinium-225 Production Facility

oncodaily - TerraPower Isotopes (TPI), the Bill Gates-founded nuclear science company, unveiled plans on March 17, 2026 to invest $450 million in a state-of-the-art actinium-225 (Ac-225) manufacturing facility in Philadelphia’s Bellwether District. The 250,000-square…

AI Summary: TerraPower announced a $450 million investment to construct a commercial Actinium‑225 production facility to supply alpha‑emitting radioisotopes for targeted cancer therapies. The plan tackles chronic supply shortages, strengthens domestic radiopharmaceutical capacity and positions the company at the center of growing demand for targeted‑alpha therapeutics — and yes, investors are watching.

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #healthcarefinance #cancerresearch #researchfunding #supplychain

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily


Back to Top / Saturday, March 21, 2026, 5:21 am / permalink 21091 / 5 stories in 2 months /

What happens to your brain in nature? The neuroscience explained

medicalxpress - Have you ever felt calmer almost as soon as you step into the woods? Or maybe noticed your busy mind soften as you look out at the sea?

AI Summary: Researchers report that immersive time in natural settings produces detectable changes in brain networks tied to attention, emotion regulation and memory. The findings suggest brief nature exposure can recalibrate neural states and boost mental health — science’s polite way of telling you to go outside instead of doomscrolling.

#healthcare #publichealth #behavioralhealth #researchfunding

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress

2 months / oncodaily

2 months / medicalxpress

2 months / medicalxpress


Back to Top / Saturday, March 21, 2026, 2:21 am / permalink 21086 / 9 stories in 2 months /

Verily raises $300M, sheds Alphabet’s majority control

Shelby Livingston / endpoints - Verily has raised $300 million in new, outside funding that ends parent company Alphabet's controlling position in the healthcare innovation company, Endpoints News has learned exclusively. The funding round was led by Series X Capital ...

AI Summary: Verily secured a $300 million financing round that reduces Alphabet’s majority control, bringing new strategic investors on board including health system partners. The cash infusion aims to accelerate Verily’s healthcare technology and platform ambitions — because nothing says “healthcare disruption” like another well‑funded pivot.

#healthcare #digitalhealth #hospitaloperations #healthcarefinance #researchfunding #venturecapital

Back to Top / Saturday, March 21, 2026, 2:21 am / permalink 21084 / 3 stories in 2 months /

Engineered tissue offers hope for children born with 'missing' esophagus

medicalxpress - Scientists from Great Ormond Street Hospital (GOSH) and University College London (UCL) have created the first lab‑grown esophagus—the food pipe—shown to safely replace a full section of the organ and restore normal function, including swallowing, in a gr…

AI Summary: Researchers report progress developing lab-grown esophageal tissue to treat children born with congenital absence or severe damage of the esophagus. Early preclinical and surgical work demonstrates that engineered tissue constructs can be implanted and integrated, offering a potential alternative to complex reconstructions — a promising step for tiny patients with very big problems.

#healthcare #biotech #infanthealth #medicaldevices #researchfunding #clinicaltrials

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress

2 months / bbc

2 months / medicalxpress


Back to Top / Saturday, March 21, 2026, 1:22 am / permalink 21081 / 5 stories in 2 months /

Rob Winn Appointed Director of NCI-Designated Fox Chase Cancer Center

oncodaily - Fox Chase Cancer Center shared a post on LinkedIn: “Temple Health – Temple University Health System today announced the appointment of Dr. Rob Winn, MD, as the next Cancer Center […]

AI Summary: Rob Winn has been appointed director of the NCI‑designated Fox Chase Cancer Center, taking the reins of clinical, research and strategic operations. His role will focus on strengthening translational research, patient care integration and institutional partnerships to advance the center's mission — you know, the usual: cure more cancer, argue less in committee meetings.

#healthcare #oncology #hospitaloperations #cancerresearch #researchfunding #clinicaltrials

2 months / oncodaily


Back to Top / Saturday, March 21, 2026, 1:21 am / permalink 21079 / 3 stories in 2 months /

Back to Top


RESEARCHFUNDING Heatmap


90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.


StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Government Policy, Gene Therapy, None, Health Disparities and look for the RSS link.


NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.